Novartis Tops Q1 EPS by 2c
Novartis (NYSE:NVS) reported Q1 EPS of $1.46, $0.02 better than the analyst estimate of $1.44. Revenue for the quarter came in at $12.53 billion versus the consensus estimate of $12.73...
Neutral
or
Novartis News & Analysis
-
-
Novartis ADR Earnings beat, Revenue misses In Q1
Investing.com - Novartis ADR reported first quarter {{erl-21133||earnings that beat analysts' expectations on Tuesday and revenue that fell short of forecasts. The firm reported earnings...
-
Novartis posts higher net profit of $2.22 billion on sales of $12.53 billion
Novartis posts higher net profit of $2.22 billion on sales of $12.53 billion
-
Novartis earnings edge higher on Cosentyx, Entresto
(Reuters) – Core operating income at Novartis edged 3% higher in the first quarter as sales growth from new drugs was partly offset by unfavourable currency effects.
-
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Aeglea Shares Additional Phase 3 Data In Inherited Metabolic Disease Aeglea BioTherapeutics...
-
Novartis to cut thousands of jobs in global revamp – paper
ZURICH (Reuters) – Swiss drugmaker Novartis will cut thousands of jobs worldwide as it combines its pharma and oncology businesses in a reorganisation announced last week, Swiss...
-
Novartis' Breast Cancer PI3K Drug, Scores FDA Approval For Ultra-Rare Indication
The FDA has granted accelerated approval to Novartis AG's (NYSE: NVS) Vijoice (alpelisib) for patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth...
-
Novartis Highlights Four-Year Efficacy, Safety Data On Kesimpta In Multiple Sclerosis
Novartis AG (NYSE: NVS) announced new long-term data from the Phase 3 ASCLEPIOS 1/2 trials and the ALITHIOS open-label extension of Kesimpta (ofatumumab) in multiple sclerosis. The data...
-
European Stocks Largely Lower; Talk of Fresh Russian Sanctions Weighs
By Peter Nurse Investing.com - European stock markets traded largely lower Monday, helped by a positive tone from Asia but talk of more sanctions on Russia over its invasion of Ukraine...
-
European Stock Futures Higher; Chinese Tech Sector, Ukraine in Focus
By Peter Nurse Investing.com - European stock markets are expected to open marginally higher Monday, helped by a positive tone from Asia, but caution reigns amid talk of more sanctions on...
-
Novartis integrates pharmaceuticals and oncology, targets savings of $1 billion
ZURICH (Reuters) – Novartis said on Monday it was integrating its pharmaceuticals and oncology units into an innovative medicines (IM) business to simplify its structure, targeting...
-
Novartis Receives Positive CHMP Opinion For Kymriah In Follicular Lymphoma, Jakavi In GvHD
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Novartis AG's (NYSE: NVS) Kymriah...
-
FDA Approves Novartis' Pluvicto As First Targeted Radioligand Therapy For Prostate Cancer
The FDA approved Novartis AG's (NYSE: NVS) Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to treat patients with a type of advanced prostate cancer that has spread to other parts of the...
-
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Novartis Announces FDA Approval Of Prostate Cancer Drug Pluvicto Novartis AG (NYSE: NVS)...
-
Novartis Suspends Some Investment, Business Activities In Russia
Novartis AG (NYSE: NVS) will suspend capital investments, media advertising, and other promotional activities in Russia but remain committed to providing access to its medicine...
-
Novartis suspends some business activities in Russia
GENEVA (Reuters) – Swiss drugmaker Novartis said on Tuesday it was suspending capital investments, media advertising, and other promotional activities in Russia but remained committed to...
-
Novartis's Data Reinforces Age-Appropriate Development With Zolgensma Gene Therapy Study
Novartis AG (NYSE: NVS) announced new data from the completed Phase 3 SPR1NT study of Zolgensma (onasemnogene abeparvovec), a one-time treatment for spinal muscular atrophy (SMA). The data...
-
NEJM Publication Shows Novartis' Kisqali With Longest Median Overall Survival In Breast Cancer Setting
The New England Journal of Medicine (NEJM) published data from Phase 3 MONALEESA-2 trial of Novartis AG's (NYSE: NVS) Kisqali (ribociclib) plus letrozole demonstrating a statistically...
-
Voyager, Novartis sign deal worth up to $1.7 billion
Voyager Therapeutics Inc.'s stock gained 16.8% in premarket trading on Tuesday after the gene therapy company said it inked a deal with Novartis [n: nvs] worth up to $1.7 billion. Novartis...
-
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative Options For...
-
Ayala Pharmaceuticals, MD Anderson Cancer Center and the Adenoid Cystic Carcinoma Research Foundation Announce Initiation of Enrollment in Window of Opportunity Study of AL101 in Adenoid Cystic Carcinoma
REHOVOT, Israel and WILMINGTON, Del., March 08, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), together with M.D. Anderson Cancer Center and the Adenoid Cystic...
-
Voyager Therapeutics Shares Jump On Novartis Option Agreement For Gene Therapy Programs
Novartis AG (NYSE: NVS) has entered a license option agreement with Voyager Therapeutics Inc (NASDAQ: VYGR) for three capsids to use in potential gene therapies for neurological diseases,...
-
European Stock Futures Higher; Fed Decision, ECB and BOE Meetings in Focus
By Peter Nurse Investing.com - European stock markets are expected to open higher Thursday as investors digest the Federal Reserve’s move to tackle inflation, ahead of policy decisions by...
-
EXPLAINER-Activists, drug groups in waiver war over COVID-19 shot patents
By John MillerZURICH, March 11 (Reuters) - A World Trade Organization (WTO) council is discussing a proposal by India and South Africa that COVID-19 vaccine and other medical patents be...
-
EXPLAINER-Activists, drug groups split over suspending COVID-19 shot patents
By John MillerZURICH, March 10 (Reuters) - A World Trade Organization (WTO) council is meeting this week to discuss a proposal by India and South Africa that COVID-19 vaccine patents be...
-
UPDATE 2-Earnings lifts European shares, German DAX outperforms
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* UBS gains after profit surge* IMF lifts global growth forecast for 2021*...
-
European stocks inch higher as UBS profit surges
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) Jan 26 (Reuters) - European shares inched higher on Tuesday after two sessions of...
-
UPDATE 2-European shares up for fourth session on stimulus, vaccine optimism
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* German DAX jumps 0.8%, Briish blue-chips fall 0.3%* BoE stands pat on policy,...
-
CORRECTED-US STOCKS-Tech sell-off hits Wall St as jobless claims remain high
(Corrects to say "the S&P 500 financials index", not "the broader financials subindex", in paragraph 5)* Weekly jobless claims stuck at high levels* Fed vows to keep rates low until 2023*...
-
CORRECTED-US STOCKS-Tech sell-off weighs on Wall St as jobless claims remain high
(Corrects headline to "jobless claims remain high", not "jobless claims rise")* Weekly jobless claims stuck at high levels* Fed vows to keep rates low until 2023* Technology stocks sell off,...
-
US STOCKS-Wall Street to open lower as labor market recovery stalls
(For a live blog on the U.S. stock market, click LIVE/ or type LIVE/ in a news window)* Weekly jobless claims stuck at high levels* Fed vows to keep rates low until 2023* Big U.S. banks fall...
-
US STOCKS-Futures slip with focus on jobless claims as Fed underwhelms
(For a live blog on the U.S. stock market, click LIVE/ or type LIVE/ in a news window)* Futures off: Dow 0.85%, S&P 1.01%, Nasdaq 0.99%By Sagarika JaisinghaniSept 17 (Reuters) - U.S. stock...
-
UPDATE 2-Faltering PMIs add to a lacklustre week for European stocks
(For a live blog on European stocks, type LIVE/ in an Eikon news window)* German, French services sectors lose momentum* FTSE 100 uninspired by surge in UK retail sales* Ireland's Kingspan...
-
REFILE-UPDATE 1-European shares limp as business recovery loses momentum
(Corrects typos in bullets two and three)* FTSE 100 uninspired by surge in UK retail sales* German manufacturing sector proves resilient in Aug - PMI* Ireland's Kingspan jumps on upbeat...
-
European shares struggle to gain, PMI data awaited
(For a live blog on European stocks, type LIVE/ in an Eikon news window) Aug 21 (Reuters) - European shares were flat on Friday ahead of business activity data that could throw light on the...
-
Top 5 Things to Know in the Market on Thursday, May 14th
By Geoffrey Smith Investing.com -- Initial jobless claims are set to ease further from their record highs, but remain at painful levels. Global stock markets have followed U.S. ones down...
-
GLOBAL MARKETS-Shares edge up as economies look to reopen
* MSCI World Index gains 0.2%* European shares flat* Brent crude up 5%* Dollar heads for two-week lows before Fed* Fed statement due around 1800 GMT* Graphic: World FX rates in 2020...
-
GLOBAL MARKETS-Shares squeeze out gains as economies look to reopen
* MSCI World Index gains 0.2%* European shares up 0.3%, FTSE up 1%* Brent crude up 5%* Dollar heads for two-week lows before Fed* Fed statement due around 1800 GMT* Graphic: World FX rates...
-
European shares inch lower as healthcare stocks drag
(For a live blog on European stocks, type LIVE/ in an Eikon news window)April 29 (Reuters) - European shares slipped on Wednesday as a slide in healthcare stocks outweighed upbeat earnings...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
